

Fanvestments Corporation
Global Investments - Global Returns
Invest today, Build Wealth Forever

FVAM Fund Quarterly Portfolio Report
Q4 - 2021

***Fanvestments FVAM Diversified Private Alternative Investment Fund
(FVAM)***

This Report describes the Fanvestments Diversified Private Alternative Investment Fund (the "Fund", "FVAM"). Fanvestments Corporation (the "Management"), a Rhode Island S-Corporation, serves as the Fund's Management Business. The following summary highlights information about the fund, during and as of the 4th Quarter of 2021, and info about the fund's investment strategy and expectations. Except where the context otherwise requires or indicates, in this report, (i) "Fanvestments," "the Business," "we," "us", "Firm", "management" and "our" refer to Fanvestments Corporation and/or owner, and its Primary offering, with respect to FVAM, a Private Alternative Investment Fund, referred to as "the Fund", "the portfolio", or "FVAM".

Contact and Social Media:

Fanvestments, Corporation

Matthew Fanning – Owner / Founder / CIO / Fund Manager

mfanning@fanvestments.com

www.fanvestments.com

Twitter: @fanvestments

facebook.com/fanvestments

Instagram: @fanvestments

PRINCIPAL INVESTMENT STRATEGY

The FVAM Fund consists of a diversified portfolio of mixed asset-types, with a majority focus on equity investments ("stocks"), as well as occasional exposure to fixed income, currency, and commodities, for the goal of capital appreciation and preservation, to drive long-term positive durable returns through all types of economic and global financial cycles. FVAM's primary exposure focus is mostly within individual stocks with a long-bias. The fund applies multiple strategies, from fundamental research looking at earnings, revenue, growth rates, and valuation, to analyzing historical data and projecting future expectations. Combining fundamentals with technical analysis ("technical"), studying charts and price action for trends, as well as trend change, price and timeframe analysis, overbought and oversold indicators, and volume spikes leading to capitulation. The macro environment is very important as well, and will overlay macro research on top of other research and overall portfolio analysis. Other strategies, more of a focus within a sector, such as biotech, looking for companies that are trying to find a cure for major diseases. Within Technology, to find innovation helping to disrupt and shape the future, such as AI, Big Data, Cloud, Analytics, FinTech (financial technology), as well as to find the Founders that are all-in and have a sense of brilliance. Price and Returns tend to trump timeframes, "PriceFrame", but the fund does expect to hold most investments for multiple years, mid-to-long term.

The Fund is actively-managed with a blended investment style, looking for Growth at a great Value, Growth-on-Sale, utilizing more of a "buy the blood" strategy - buy low-sell high, as a fundamental mindset. Fund will also seek to find opportunities within event-driven strategies, such as mergers, FDA approvals, momentum and fund flows, as well as unusual options action and potential buy-out/merger opportunities. Part of the investment style is to bring together a diversified multi-asset "401k retirement" portfolio approach, combined with hedge fund, institutional style investing involving individual stock picking alongside minimal hedging against general market risk, as well as having low market correlation producing fund-specific returns. "401k meets Alternative Investment fund". The FVAM fund will also invest in other investment funds, indexes, and ETFs from time to time, for opportunity and to obtain that much more diversification, and to lower overall volatility and risk. Only on a limited basis, and kept to very small exposure at most times, the fund does use multiple hedging strategies to protect from general stock market volatility, as well as downside risk within individual positions, or macro issues such as economic cycles, recessions, geopolitics. In most hedge cases, the fund will utilize options strategies for short exposure vs outright selling short, such as index/ETF options, VIX (volatility) options, positional hedges (puts or covered calls). Overall hedging exposure is kept low, utilizing more of a hedge by allocation strategy. Such as Diversification and Position sizing - asset allocation management, always monitoring positional exposure relative to the risk of that position and overall portfolio size. As well as other portfolio management strategies such as performance monitoring and risk management, constantly studying fund volatility and day-to-day performance statistics.

Another major objective of this fund is to begin replacing a portion of the "40" of a typical "60-40" portfolio, where 60% is towards stocks, 40% in Bonds. This bond exposure is mostly meant to reduce volatility and risk in a portfolio, with bonds normally having a lower return. FVAM's risk management strategy and diversification should also reduce overall risk relative to stock investing, but have a much higher probability to far outperform bonds and CDs. Since FVAM is not intending to mirror, or match the assets or performance of any other index or ETF, the fund's performance will not have any intention to directly match the performance of any other investment vehicle, ETF, or Index or have the same timing as the overall markets. An index, like the S&P 500, is also a collection of assets, with ~500 individual stock holdings. FVAM's intent is to have created its own unique investment vehicle, a diversified multi-asset fund (stocks, bonds, ETFs), with individual assets selected by Fanvestments Management, minimal market correlation, and less volatility vs market indices. Although compared to the S&P 500, this is not the fund's true benchmark, as the index is a US large-cap index. FVAM is diversified among multiple market caps, multiple strategies, and has international exposure. Utilizing a dynamic and perpetually improving investment strategy combining increased Portfolio Quality, constant Portfolio analysis, non-stop financial market study, risk and allocation management, along with relentless analysis of performance metrics, mathematics and statistics, with the goal of perpetual improvement. Matching up technical analysis for timing with Fundamental analysis for valuation, and overlaying Macro environment research to help find Global trends and determine overall Market risk.

Make the Money Make More Money.

Q4 Highlights

For the 4th Quarter of 2021, the FVAM fund finished higher, producing a 6.23% return, the fund's best quarterly return for the year. The fund was up 2.9% in October, down -0.35% in November, and up 3.7% in December. On a Year-to-Date basis, for 2021, FVAM finished up 7.02%. For the Quarter, the S&P 500 was up about 5.73%, with the small cap etf IWM, up 2.24%. The ACWX etf, which tracks stocks around the world excluding the United States, was up 0.56% for the quarter. Cathie Wood's ARKK growth & innovation fund, was down just under -10%. Although there is no attempt to match the performance or timing of the S&P 500, along with mixed-asset exposure, multi-cap and multi-strategy, lower risk & volatility, and with equity exposure around 80% of the fund, the fund's performance and volatility is analyzed against the index, an all-stock and strictly large-cap index. Another reference point, a more relative and important comparative benchmark for the fund, is Warren Buffett's Berkshire Hathaway. Using the BRK/b shares, Berkshire was up ~9.4% for the 4th quarter of 2021. Looking into the 1st Quarter of 2022 thru February, overall markets have started out lower, with the S&P 500 down just over 8%, while FVAM is also down but outperforming that index by 4.1%

The fund's top performing investments for the year, were Advanced Micro Devices (AMD), Tilray (TLRY) and Vir Biotechnology (VIR) as the top three. Following them up was Apple (AAPL), Sofi Technologies (SOFI), Lucid Group (LCID), Salesforce (CRM), crypto Ethereum (via grayscale's ETHE), Baidu (BIDU), and Abbvie (ABBV) rounding out the top 10 performing investments. Of those top 10; Tilray, Vir Biotech, Lucid, Ethereum, and Baidu have all been sold in full for sizable gains. AMD, Apple, Salesforce, and Abbvie continue to be longer-term investments. Sofi was sold-in-full early in the 4th quarter in the mid-20's, started re-buying in mid-December and have been cost averaging back in between \$9-\$15/share. Fund trimmed its position in Vertex slightly, and more just for portfolio risk management, as position size has grown with upside, personally my favorite "high class problem" to have. In the quarter, the fund increased core investments in Apple (AAPL), Coupang (CPNG), Carnival Cruise Lines (CCL), and Splunk (SPLK). Positions in GCP Applied Tech (GCP) and DraftKings (DKNG), were sold in full for profits, while Canopy Growth (CGC) was sold at a loss. New core positions started in fintech Paypal (PYPL) and gene editing Crisper (CRSP). Looking further into Abbvie, the fund began buying ABBV back in early 2020 around \$81 and bought through the quarter, also added in the 4th Quarter of 2020 as well. With an average price around \$82.50, Abbvie is currently trading above \$150, almost producing a double return, and the fund remains bullish on the stock. Based on its Q4 earnings report, Abbvie produced Quarterly revenue of \$14.9 billion, \$56.2 billion in Revenue for the year. They earned \$6.45/share, an increase of 137%, and raised guidance for full-year 2022 EPS looking for above \$9.30. Target price just above \$200 going out a year.

Can read more about Abbvie here : [Abbvie Q4 2021 Financial Results](#)



Looking into Q1 2022, a new core position was initiated in Mosaic (MOS) and a smaller spec position started in Virgin Galactic (SPCE). Positions in Bitcoin Fund GTBC and crypto miner Hut Mining (HUT) were sold almost in full, keeping a smaller options position in HUT. Increased positions in Crisper, Salesforce, Coupang, Paypal, AMD, and Sofi. Coupang has been a tough investment so far, but still have full conviction in its longer-term opportunity. Fund has an avg. cost ~\$34/share for CPNG, with the stock currently around \$20. They grew revenue over 50% year-over-year to \$18.6 billion, but still remain unprofitable, which in 2022, the overall markets have zero patience for. Current price-target looking out a year at \$55, about 175% upside, using 4x expected 2022 Revenue. Longer-term price target, looking out 3-4 years, over \$200/share, just about a 10-fold increase from current levels. Using 5x revenue with 40% revenue growth year-over-year, which would see Coupang making over \$70 billion in revenue by 2025.

Can read more about Coupang here: [Coupang Investor Presentation](#)



Crisper Therapeutics (CRSP), is a biotech firm with a focus on Gene-Editing technology. They are working on the development of gene-based medicines, utilizing CRISPR/Cas9 gene-editing for serious and rare diseases, such as blood diseases, Cancer, Sickle Cell, and diabetes. CRSP stock can be very volatile, with the stock reaching over \$200/share in 2021, and down to \$50 in early 2022. Fund started buying CRSP in December '21 around \$80 and has been dollar-cost averaging since with an average cost just above \$74, with the stock around \$65 in early March. Current Price-target at \$131.

Can read more about Crisper here: [Crispr Corporate Overview](#)

Below shows reporting created & analyzed within Data Analytics software, Tableau Software, which has data integration into the fund's internal database/spreadsheets. (*Portfolio Data as of Feb 2022)
High Level allocation heat map and pie chart:




Below shows the further breakdown of only the fund's individual stock exposure. Currently, the heaviest focus of that exposure is allocated towards the Technology sector, as well as the Healthcare / Biotech sector



Performance Analysis: Analyzing the breakdown of the Fund's performance, as well as comparisons to other investment vehicles/index, such as the S&P 500, \$BRK-b (Warren Buffett's 'Berkshire Hathaway'), ACWX which tracks Global Markets minus the US (World x-US), and the Russell 2000 small cap index (\$IWM)


FVAM fund, 4th Quarter 2021 , Weekly




FVAM fund, One-Year (Full Year 2021), Weekly




FVAM fund (green) vs SPX (S&P 500, orange), Q4 2021, weekly




FVAM fund (green) vs SPX (S&P 500, gray), Q4 2021, Daily




FVAM fund (green, left) vs BRK/b (blue, right), 2021 Full-Year (thru October), Weekly
 (\$BRK-B : Berkshire Hathaway B-shares)




FVAM fund (green, left) vs BRK/b (blue, right), Q4 2021, Weekly




FVAM vs BRK/b and relative return (FVAM vs BRK/b), weekly, YTD into Q1 2022
 (excess: positive = outperformance, negative = underperformance)




FVAM vs BRK/b and relative return (FVAM vs BRK/b), weekly, Q4 2021
 (excess, positive = outperformance, negative = underperformance)




FVAM (Green) vs S&P500 vs IBB (BioTech Index Fund) vs BRK/b (Berkshire Hathaway) , 4th Quarter - 2021




FVAM (green) vs S&P500 vs BRK/b (Berkshire Hathaway) vs ACWI (World Index) vs IBB (BioTech Index Fund) vs LQD (Bonds) vs EEM (Emerging Markets), Q4 - 2021




FVAM vs SPX and relative return (FVAM vs SPX), Q4 - 2021, weekly
 (*excess return shows FVAM vs SPX, shows by how much FVAM is outperforming or underperforming the S&P 500)




FVAM vs SPX and relative return (FVAM vs SPX), Q4 - 2021, Daily




FVAM vs IWM (small caps) vs IBB (biotech) vs SPX (S&P 500) vs ACWI (world index) vs ACWX (world x-US) vs LQD (bonds), Weekly, Q4




FVAM vs S&P 500 (\$SPX) vs Berkshire Hathaway (\$BRK/b) vs \$ACWX (World Index x-US), Daily, Q4




FVAM (green) vs EEM (Emerging Markets) , Year-to-Date '21 (thru Jan 2022), Weekly




FVAM (green) vs LQD (Investment Grade Corporate Bonds), YTD '21 (thru Jan 2022), Weekly



S&P 500 (orange) vs ACWX (World Index minus U.S.), Q4 2021, Weekly



FVAM vs ACWI (World Index), with Relative Return (excess return), Q4 2021, Weekly



FVAM (green) vs ACWX (World Index minus USA, blue) vs S&P 500 (orange),
 Year-to-Date (full-year 2021), monthly returns



Heat Map for the S&P 100 Large-Cap Index, showing each stock within that index/sector along with its relative size and weight compared to the overall index (**larger the block size the larger percentage that stock makes up within the index**)
 (*as of Feb 2022)

